Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer

Carcinogenesis

Volumn 32, Issue 12, 2011, Pages 1867-1871

  Yin, Jikai ^a   Lu, Charles ^a   Gu, Jian ^a   Lippman, Scott M ^a   Hildebrandt, Michelle A T ^a   Lin, Jie ^a   Stewart, David ^a   Spitz, Margaret R ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHECKPOINT KINASE 2; CISPLATIN; CYCLIN B2; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 1; PROTEIN P73; RB1 PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE DOSAGE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 81855166110     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr217     Document Type: Article

References (39)

1. Aggarwal, C. et al. (2010) Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J. Natl Compr. Canc. Netw., 8, 822-832.
2. Coate, L.E. et al. (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol., 10, 1001-1010.
3. Petrelli, F. et al. (2009) Is there a role for maintenance therapy in non-smallcell lung cancer? An emerging issue. Expert Rev. Anticancer Ther., 9, 1455-1465.
4. Poehlmann, A. et al. (2010) Importance of DNA damage checkpoints in the pathogenesis of human cancers. Pathol. Res. Pract, 206, 591-601.
5. Vermeulen, K. et al. (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif., 36, 131-149.
6. Hartwell, L.H. et al. (1989) Checkpoints: controls that ensure the order of cell cycle events. Science, 246, 629-634.
7. Malumbres, M. et al. (2001) To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer, 1, 222-231.
8. Park, M.T. et al. (2003) Cell cycle and cancer. J. Biochem. Mol. Biol., 36, 60-65.
9. De Luca, A. et al. (2003) Cyclin T: three forms for different roles in physiological and pathological functions. J. Cell. Physiol., 194, 101-107.
10. Sherr, C.J. (1994) G1 phase progression: cycling on cue. Cell, 79, 551-555.
11. Neganova, I. et al. (2008) G1 to S phase cell cycle transition in somatic and embryonic stem cells. J. Anat., 213, 30-44.
12. Vogelstein, B. et al. (2000) Surfing the p53 network. Nature, 408, 307-310.
13. Tozluoglu, M. et al. (2008) Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis. Nucleic Acids Res., 36, 5033-5049.
14. Lobrich, M. et al. (2007) The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat. Rev. Cancer, 7, 861-869.
15. Malumbres, M. (2007) Cyclins and related kinases in cancer cells. J. BUON, 12 (suppl 1), S45-S52.
16. Danesi, R. et al. (2009) Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv. Drug Deliv. Rev., 61, 408-417.
17. Kastan, M.B. et al. (2004) Cell-cycle checkpoints and cancer. Nature, 432, 316-323.
18. Dai, J. et al. (2011) Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS One, 6, e21120.
19. Pu, X. et al. (2010) PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer, 71, 82-88.
20. Oken, M.M. et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5, 649-655.
21. Wu, X. et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev. Res. (Phila.), 2, 617-624.
22. Norbury, C. et al. (1992) Animal cell cycles and their control. Annu. Rev. Biochem., 61, 441-470.
23. Massague, J. (2004) G1 cell-cycle control and cancer. Nature, 432, 298-306.
24. International HapMap Consortium. The International HapMap Project. (2003). Nature, 426, 789-796.
25. Sherry, S.T. et al. (1999) dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res., 9, 677-679.
26. Benjamini, Y. et al. (1995) Controlling the false discovery rate-a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B. Stat. Methodol., 57, 289-300.
27. Garcia-Closas, M. et al. (2007) Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet., 3, e29.
28. Mountzios, G. et al. (2010) Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. Crit. Rev. Oncol. Hematol., 75, 94-109.
29. Olaussen, K.A. et al. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med., 355, 983-991.
30. Zhou, W. et al. (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res., 10, 4939-4943.
31. Wu, X. et al. (2008) Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinumbased chemotherapy. Pharmacogenet. Genomics, 18, 955-965.
32. Ma, H. et al. (2010) Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer in a Chinese population. Lung Cancer, 73, 32-37.
33. Pucci, B. et al. (2002) pRb2/p130 promotes radiation-induced cell death in the glioblastoma cell line HJC12 by p73 upregulation and Bcl-2 downregulation. Oncogene, 21, 5897-5905.
34. Lin, K.W. et al. (2004) Multiple stress signals induce p73beta accumulation. Neoplasia, 6, 546-557.
35. Wakatsuki, M. et al. (2008) p73 protein expression correlates with radiation-induced apoptosis in the lack of p53 response to radiation therapy for cervical cancer. Int. J. Radiat. Oncol. Biol. Phys., 70, 1189-1194.
36. Baker, G.L. et al. (2005) Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle, 4, 330-338.
37. Knudsen, E.S. et al. (2008) Tailoring to RB: tumour suppressor status and therapeutic response. Nat. Rev. Cancer, 8, 714-724.
38. Noel, E.E. et al. (2010) The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am. J. Pathol., 176, 2607-2615.
39. Ewen, M.E. (1994) The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev., 13, 45-66.